PLC Systems Inc. (OTCBB: PLCSF), a medical device company focused on innovative technologies for the cardiac and vascular markets, today announced that its lead product, RenalGuard ®, will be featured during Prevention of Contrast-Induced Kidney Injury: Focus on Hydration & New Frontiers, a 90-minute discussion session at Transcatheter Cardiovascular Therapeutics (TCT) 2012, being held October 22-26, 2012 at the Miami Beach Convention Center. As part of its participation in this important conference, PLC will demonstrate RenalGuard in its booth (#805) and RenalGuard will also be displayed in the ACIST Medical Systems booth (#673) and in the Twins and Martin Equipment booth (#692) through Girlow USA. ACIST is PLC’s distributor in France and Germany, and Girlow is PLC's distributor in Latin and South America excluding Brazil. Mark R. Tauscher, president and chief executive officer of PLC Systems, said, “We continue to see an increased focus worldwide on the issue of acute kidney injury caused by the use of contrast during imaging procedures, otherwise known as contrast-induced nephropathy (CIN). The development of CIN results in a range of serious and potentially deadly outcomes in patients who already have compromised kidney function, and clinical data continue to show that the use of RenalGuard and its associated therapy can reduce the incidence of this condition in at-risk patients.” Mr. Tauscher continued, “This year’s TCT expects to attract a large international audience, which will provide us with increased exposure in countries where we are currently selling RenalGuard, including Latin America, South America and Europe. Current projections indicate that more than 60% of this year’s attendees will come from countries where RenalGuard is currently available through our network of distributors.” Prevention of Contrast-Induced Kidney Injury: Focus on Hydration & New Frontiersis a 90-minute discussion of prevention techniques and therapies including RenalGuard and its associated matched fluid replacement therapy, and will include the principal investigators of the MYTHOS trial, Dr. Antonio Bartorelli, and the principal investigator of the REMEDIAL II trial, Dr. Carlo Briguori. Both trials demonstrated that patients treated with RenalGuard had a lower incidence rate of CIN compared with those treated with the current standard of care. It is one of a number of sessions related to CIN at this year’s conference, and takes place Friday, October 26, from 12:15 p.m. to 1:45 p.m. local time. TCT is sponsored by the Cardiovascular Research Foundation, and more than 12,000 clinicians and professionals from around the world are expected to attend this year’s event.